Skip to main
TVRD

TVRD Stock Forecast & Price Target

TVRD Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 17%
Sell 17%
Strong Sell 0%

Bulls say

Tvardi Therapeutics is well positioned to capitalize on the high unmet need for effective therapies targeting STAT3. Its pipeline includes two oral, small molecule drugs with promising early results and improved tolerability. With enough funding to continue operations until late 2026, the company is expected to drive value for its shareholders by advancing its innovative drug candidates through clinical trials.

Bears say

Tvardi Therapeutics is a clinical-stage biopharmaceutical company developing novel, oral, small molecule therapies to target STAT3 for the treatment of inflammatory and proliferative diseases. While Tvardi's pipeline drugs, TTI-101 and TTI-109, show some promise in early clinical data, Tvardi faces significant risks, including competition in the HCC market, potential financing issues, and the structural limitations of targeting the SH2 domain of STAT3. These factors, combined with a negative market perception following a recent trial miss, lead to our cautious outlook on the company's stock.

TVRD has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cara Therapeutics Inc (TVRD) Forecast

Analysts have given TVRD a Buy based on their latest research and market trends.

According to 6 analysts, TVRD has a Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cara Therapeutics Inc (TVRD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.